Form D · Biotechnology
CORVIDIA THERAPEUTICS, INC.
Waltham, MA · CIK 0001739146
Offering snapshot reported May 1, 2018 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 18, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 1, 2018 | Initial | $59,999,979 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-311385
Source: Form D, filed May 1, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ram Aiyar | Executive |
| Marc De Garidel | Director, Executive |
| Sylvie Gregoire | Director |
| Karim Helmy | Director |
| Aaron Kantoff | Director |
| Tyrell Rivers | Director |
| Graziano Seghezzi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
35 Gatehouse Drive
Waltham, MA, 02451
Waltham, MA, 02451